PharmaVoice Logo

Healthcare Leaders Hub

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

ET Pharma

Nov 4, 2026, 12:33 PM

HRV Pharma acquires trial drugs sourcing firm Phatebo

Phatebo GmbH, founded in 2015, sources investigational, comparator and ancillary medicines, for innovators, and clinical research organisations.

Pharma Tech

Nov 4, 2026, 11:51 AM

Trump’s healthcare plans under contention after Democrats’ midterm landslide 

Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

Pharma Tech

Nov 4, 2026, 11:39 AM

Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn

The collaboration will focus on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies across six programmes.

Pharma Tech

Nov 4, 2026, 11:36 AM

AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera 

AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.

PharmaShots

Nov 4, 2026, 11:26 AM

Idorsia Receives the US FDA’s Breakthrough Therapy Designation for Daridorexant to Treat Pediatric Insomnia Disorder

Shots: The US FDA has granted Breakthrough Therapy Designation to Idorsia‘s daridorexant, a dual orexin receptor antagonist (DORA), for the treatment of insomnia disorder in pts aged 10 to <18yrs. The designation was supported by a P-II dose-finding study (n=165), which showed a significant dose-dependent improvement in total sleep time (p=0.0185); a single 50mg dose
 The post Idorsia Receives the US FDA’s Breakthrough Therapy Designation for Daridorexant to Treat Pediatric Insomnia Disorder appeared first on PharmaShots.

PharmaShots

Nov 4, 2026, 11:21 AM

Graviton BioScience Receives the US FDA’s Fast Track Designation for GV101 to Treat Friedreich’s Ataxia

Shots: The US FDA has granted Fast Track Designation to Graviton BioScience‘s GV101, an oral, selective ROCK2 inhibitor, for the treatment of Friedreich’s ataxia (FA), following the recent clearance of its IND Graviton is initiating a 12wk., randomized, PBO-controlled, dose-finding P-II trial of GV101 in pts with FA, with first enrollment at US sites expected
 The post Graviton BioScience Receives the US FDA’s Fast Track Designation for GV101 to Treat Friedreich’s Ataxia appeared first on PharmaShots.

News

Latest industry coverage

Google News

Nov 4, 2026, 8:04 PM

What Does ‘Compromise’ Mean for 340B Drug Pricing Program? - AIDS Healthcare Foundation

What Does ‘Compromise’ Mean for 340B Drug Pricing Program?  AIDS Healthcare Foundation

Google News

Nov 4, 2026, 7:54 PM

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Gets Price Target Increase from TD Cowen - MarketBeat

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Gets Price Target Increase from TD Cowen  MarketBeat

Google News

Nov 4, 2026, 7:15 PM

Finnish biotech firm Volare targets full production at insect protein factory in 2027, unveils plans for second facility - SeafoodSource

Finnish biotech firm Volare targets full production at insect protein factory in 2027, unveils plans for second facility  SeafoodSource

Google News

Nov 4, 2026, 6:47 PM

Novo’s race to catch Eli Lilly may already be lost - Endpoints News

Novo’s race to catch Eli Lilly may already be lost  Endpoints News

Google News

Nov 4, 2026, 6:45 PM

Boehringer forges $7bn alliance with China's SBP Group - pharmaphorum

Boehringer forges $7bn alliance with China's SBP Group  pharmaphorum

Google News

Nov 4, 2026, 6:34 PM

Govt proposes immediate licence suspension for substandard drugmakers - Business Standard

Govt proposes immediate licence suspension for substandard drugmakers  Business Standard

Google News

Nov 4, 2026, 6:28 PM

Sun Pharmaceutical Industries sales rise 11.8% to INR161,000 million - Multibagg AI

Sun Pharmaceutical Industries sales rise 11.8% to INR161,000 million  Multibagg AI

Google News

Nov 4, 2026, 6:22 PM

India's first dengue vaccine due in 2027: Japanese pharma. - en.etemaaddaily.com

India's first dengue vaccine due in 2027: Japanese pharma.  en.etemaaddaily.com

Google News

Nov 4, 2026, 5:50 PM

The Best Negotiation Training and Consulting Firms for Pharmaceutical, Biotech and Medical Device Companies in 2026 - The Canary

The Best Negotiation Training and Consulting Firms for Pharmaceutical, Biotech and Medical Device Companies in 2026  The Canary

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer